Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Download your Brochure
Reserve your place

The industry changing agenda

Achieve Real-World Enlightenment
Create convergence in patient centricity and real-world data in clinical development
  • Understand the benefits of RWE reapplication in your clinical trials for improved patient identification and recruitment
  • Develop marketing tools through-out development to help your access colleagues provide evidence on specific patient populations
  • Re-approach patient engagement to suit the new needs in the era of big data

Pfizer Christopher Boone Vice President, Head of Real World Data and Analytics Center of Excellence Pfizer

Panel: The future of pharma requires a value shift
  • Change starts within: how to move towards investing in value beyond short-term wins
  • Why pharma must take the lead to build bridges across the healthcare ecosystem
  • How pharma can help stakeholders align to reduce costs and improve patient value

Boehringer Ingelheim Martina Flammer SVP, Customer Value Boehringer Ingelheim

GSK Martin Marciniak VP, US Medical Affairs, Customer Engagement, Value, Evidence and Outcomes GSK

EMD Serono Zhen Su SVP, Chief Medical Officer, North America EMD Serono

Moderator: Aetion Scott Musial Head of Client Delivery Aetion

Prove the value of digital medicine – the case of Abilify MyCite
  • Learn how to overcome challenges commercializing digital technologies
  • Understand payer needs for creating long-term, outcomes-based agreements for digital products
  • The next steps in scaling digital products to revolutionize healthcare delivery and understanding

Otsuka John Bardi VP, Public Affairs & Digital Health Business Development Otsuka

  1. It’s a trust issue: discuss strategies for pharma and payer to achieve greater levels of partnership and decrease perceptions of data bias
  2. Europe’s GDPR tremor: is a shift in US privacy regulation around the corner? Discuss the impact new EU regulations are already having and how they might alter the US system
  3. Real-time patient insights: explore how to overcome issues with data quality and trust from the new era of digital devices
  4. Predict outcomes: learn how to work with payers to model patient populations
  5. Social media as a source of RWE: discuss how emerging technologies such as Natural Language Processing (NLP) are being used to find new patient insights
  6. The use of RWE in clinical trials: debate how to best incorporate big data insights into the development process, keeping high data relevance and quality
  7. Agree on outcomes: discuss experience and best practices on effective communication with payers and agreeing on desired outcomes
  8. The pragmatic solution: explore different approaches to defining the right question for pragmatic studies
  9. One standard to rule them all: learn about developments in data standardization techniques and discuss whether a standardized model is the best approach to harmonizing data silos
  10. Put your house in order first: discuss difficulties and different approaches on how best to place internal RWE expertise for the most effective knowledge dissemination
  11. Real-world patients: how can pharma engage with patients regarding ownership and data use?
  12. Learning healthcare systems: harmonized HEOR - but how feasible are these systems and what’s a realistic timeframe for their development?
Stakeholder Partnerships for Outcomes-Based Healthcare
FDA real-world evidence vision and policy
  • Implementation of the 21st Century Cures Act
  • FDA real-world demonstration projects – Exploring the future

FDA Khair ElZarrad Deputy Director, Office of Medical Policy FDA

Are Employers the new gatekeepers to access?
  • Essential briefing on how employers view the changing access landscape
  • How do employers view value and where do they differ from payers?
  • Can pharma contract directly with employers? Is this the next frontier for value-based contracting?

National Alliance of Healthcare Purchaser Coalitions Michael Thompson President & CEO National Alliance of Healthcare Purchaser Coalitions

Mid-America Coalition on Health Care Troy Ross President & CEO Mid-America Coalition on Health Care

Payer-pharma data sharing: you can’t do it alone
  • Why early engagement makes increasing sense
  • Tackle bias with transparent and collaborative models
  • Walk through an example of mutual data sharing in oncology
  • Set your third-party strategy: how to balance external party evidence generation against higher costs and complexity

GSK Amanda Bruno Head of Value, Evidence and Access, Oncology GSK

Strategic Collaborations with hospital & provider systems, IDNs and ACOs to bring value-based care to patients
  • Investigate success factors for meaningful pharma provider systems engagement
  • Explore opportunities for implementation of VBC programs using population health
  • Discuss unique advantages of direct-to-system collaborations over traditional payer engagements
  • Learn how to leverage real-world evidence programs and risk-based contracting

Moderator: Pharmvivo Ulrich Neumann Founder Pharmvivo

Astellas Americas Shontelle Dodson SVP and Head, Medical Affairs Astellas Americas

Company Gergana Zlateva VP, Payer Insights and Access Pfizer Oncology

Sunovion Pharmaceutical Matt Portch Vice President, Managed Markets Sunovion Pharmaceutical

Regional Cancer Care Associates Terrill Jordan President & CEO Regional Cancer Care Associates

Scale Value-Based Contracting
Panel: The Roadmap to Scale VBC
  • What lessons can we learn from failure of previous attempts at VBC?
  • Case Study: How Aetna and Merck created their VBC for Januvia
  • Create incentives to align partners and scale the adoption of VBC

National Pharmaceutical Council Dan Leonard President National Pharmaceutical Council

Aetna Harry Vargo Director of Value Based Contracting and Manufacturer Trade Relations Aetna

Merck David Hartenbaum Executive Director, Account Management Merck

Use data, analytics, and services to assess and monitor the value of healthcare products
  • Establishing transparency in data sources and methods used to determine product value
  • Fostering trust between payer/manufacturers as partners in contracting
  • Building a scalable approach to value-based contracting for long-term benefits

IBM Watson Health Denise Meade Director of Product Management IBM Watson Health

Create a Multi-stakeholder and Integrated Blueprint for VBC: A Medical Affairs Perspective
  • Collaboratively define VBC driven endpoints with payers and strategize the burden of evidence
  • Integrate provider perspectives to drive VBC adoptions and support for evidence generation
  • Set patient at the center of VBC strategy and generate a payer-patient value chain

Acer Therapeutics Usman Iqbal MD, MPH, MBA Vice President, Medical Affairs Acer Therapeutics

Do Providers and Accountable Care Organizations support the shift to value-based care?
  • Understand the differences between ACO and traditional payer perspectives on VBC
  • What additional support do you need to give to providers and ACOs in order to implement VBC?
  • Hear from the provider: This is pharma’s do list to scale VBC
Panel: Communicate and contract for value in an evolving legal landscape
  • Discuss recent FDA final guidance on use of Health Economic Information
  • Update on the status of existing and new safe harbors impacting value based contracting
  • Understand compliant use of dynamic data modeling and RWE when working with payers and providers 
  • Best practices in contracting for use of digital health platforms and data when designing value based offers 

Covington Rujul Desai Of Counsel Covington

Abbvie Brad Patrick Division Counsel Abbvie

Covington Michael Labson Partner Covington

Market Access Strategy
Improve Access Through Value to The Patient
  • Determine when to deploy co-pay programs to boost patient access
  • How to boost wellness by supporting patients with outcome data
  • Is VBC truly patient-centric?

Otsuka Desiree Priestley Associate Director, ASSURE Strategic Access Operations Otsuka

Panel: Can we work directly with IDNs and ACOs to bring in VBC?
  • Where do VBC models need to adapt vs. traditional payer collaborations
  • Can pharma form direct partnerships with health systems?
  • Where do hospital systems require support to overcome data-driven difficulties?

Speakers TBA

Case Study: How Discover Diabetes is setting new standards for global epidemiology
  • The story behind AstraZeneca's platform to enrol patients from >35 countries in a global study of diabetes treatment and outcomes
  • Identification of the drivers of diabetes care across the world
  • How to pull through best practices for multi-country real-world studies

AstraZeneca Eric Wittbrodt Director, Epidemiology AstraZeneca

Mastery of Real-World Evidence
Panel: Build a robust American data ecosystem
  • Build trust in RWE amongst regulators and payers by aligning data standards with competitors
  • Work directly with IDNs and providers to fix gaps and align efforts towards a unified data capture strategy & breaking data silos
  • Explore the industry actions required to reshape public perception of data sharing and ownership

Boehringer Ingelheim Anjan Chatterjee VP, Global Head RWE - COE, Epidemiology and Big Data Boehringer Ingelheim

Celgene Patrick Loerch Senior Director, Data Sciences (Information, Knowledge Utilization - iKU) Celgene

Vertex Pharmaceuticals Denise Globe VP, Head Global Real World Evidence Center of Excellence Vertex Pharmaceuticals

Future approaches to generate robust Real World Evidence
  • Address current gaps in real world data generation
  • Find the right data for your study with automated data source mapping
  • Create new cost efficiencies in data generation with the use of novel technologies

Takeda Jefferson Tea Vice President, Medical & Scientific Affairs Takeda

Address bias in comparative effectiveness to set RWE strategy capable of growing access
  • How to map patient sub-populations to determine if your target population is sufficiently heterogeneous
  • Assess benefit risk across in sub-populations to determine validity of RWE
  • Shift from evidence to cost-effectiveness, and measure value across populations

Sanofi Riccardo Perfetti Senior Medical Officer, Vice President Global Medical Affairs, Diabetes Division Sanofi

Case study: Accelerate clinical development leveraging real-world data
  • Inform phase 3 trial design by enabling clinical colleagues to define endpoints and inclusion criteria more accurately
  • See how Lilly adapted traditional FDA submission standards to incorporate new levels of patient/population understanding from RWE sources

Eli Lilly Diana Stefani-Hunyady Global Senior Director, IL-23 Medical Affairs Launch Lead Eli Lilly

Accelerate therapeutic development with blockchain technology – the case for a drug development meritocracy
  • Discuss the impact of blockchain on data ownership and the breaking down of data silos
  • Explore use case examples of blockchain technology in patient registries and genomic matching
  • Build industry trust in blockchain through the reputation systems: KYC – Know Your Customer, Collaborator, Clinician

Mitsubishi Bryan Hill Medical Science Director Mitsubishi

Use Natural Language Processing (NLP) and machine learning to radically improve the efficiency of data-driven Strategy
  • Your briefing on the essential NLP innovations to unlock hidden value in your data (Linguamatics)
  • Create your vision to build internal capacity to accept new technology through training and partnerships
  • How to take advantage of new capabilities to combine, use and extract data while staying compliant

Download your event brochure today

Complete speaker line-up • Program for all tracks & sessions • Audience breakdown